{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:06:48Z","timestamp":1784041608210,"version":"3.55.0"},"reference-count":21,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2022,7,3]]},"DOI":"10.1080\/10428194.2022.2087072","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:20:33Z","timestamp":1655270433000},"page":"1771-1773","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"63","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Department Hematology, Hull University Teaching Hospitals NHS Trust","place":["Hull, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David John","family":"Allsup","sequence":"additional","affiliation":[{"name":"Department Hematology, Hull University Teaching Hospitals NHS Trust","place":["Hull, UK"]},{"name":"Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull","place":["Hull, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Polliack","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah-Hebrew-University Medical Center","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00870-w"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2045597"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0074-z"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-860593"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004824"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05469-y"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_1_21_1","first-page":"LB 1900","article-title":"First interim analysis of ALPINE study: results of phase III randomized study of Zanubrutinib versus ibrutinib in patients with relapsed\/refractory CLL\/SLL","author":"Hillmen P","year":"2021","unstructured":"Hillmen P, Eichhorst B, Brown JR, et\u00a0al. First interim analysis of ALPINE study: results of phase III randomized study of Zanubrutinib versus ibrutinib in patients with relapsed\/refractory CLL\/SLL. Eur Hematol Assoc. 2021;:LB 1900.","journal-title":"Eur Hematol Assoc"},{"key":"e_1_3_1_22_1","first-page":"EP1743","article-title":"Living with CLL: a quantitative cross-sectional study of Italian patients on behalf of AIL (associazione italiana contro le Leucemie-Linfomi e mielomi)","author":"Molica S","year":"2020","unstructured":"Molica S, Bombaci F, Cuneo A, et\u00a0al. Living with CLL: a quantitative cross-sectional study of Italian patients on behalf of AIL (associazione italiana contro le Leucemie-Linfomi e mielomi). Eur Hematol Assoc. 2020;:EP1743.","journal-title":"Eur Hematol Assoc"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2022.2087072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2022.2087072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2022.2087072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:39:09Z","timestamp":1784039949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2022.2087072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,7,3]]}},"alternative-id":["10.1080\/10428194.2022.2087072"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2022.2087072","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}